MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2025. Key highlights include:

(CAD) Q2 2025 % Change

vs.

Q2 2024 H1 2025 % Change

vs.

H1 2024 Trailing Twelve

Months

(TTM)

June 30, 2025 % Change

vs.

TTM

June 30, 2024 Canadian Pharma Sales 9,327,224 +9% 18,486,876 +15% 35,336,401 +12% International Pharma Sales 445,614 +183% 1,980,830 +1160% 2,753,588 129% Total Company Sales 10,179,296 +14% 21,158,256 +27% 39,510,951 +17% EBITDA1 2,760,149 +35% 5,961,796 +40% 11,052,544 +26% Net Income After Taxes (NIAT) 2,018,171 +28% 4,338,104 +30% 8,259,192 +16% Fully Diluted EPS 0.18 +31% 0.38 +33% 0.72 +20%

Return on Average Equity for TTM June 30, 2025 was 23% as compared to 21% for TTM June 30, 2024

During H1 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB)

Paid quarterly cash dividends of $0.05 per common share on March 14, 2025 and June 13, 2025

Declared subsequent cash dividend of $0.05 per common share to be paid on September 15, 2025

“Each of our Canadian Pharma, International Pharma, and Legacy businesses continued to perform well during Q2 2025, delivering 14% sales growth and 28% net profit growth overall,” commented Mr. René Goehrum, President and CEO of BioSyent. “Led by FeraMAX® Pd and Tibella® (tibolone), Canadian Pharma sales grew by 9% overall for the quarter, in spite of uncertainty in the Canadian economy from the ongoing threat of tariffs. Our International Tibelia® (tibolone) business also continued to perform to our expectations in Q2 2025, with year-to-date incremental revenues of $1.3 million following our September 2024 acquisition of the worldwide rights to this product. Though our overall gross margins have tightened with changes in product mix, our net profit margin improved to 21% of sales in H1 2025 from 20% in the comparative period with an overall reduction in our operating expense ratio.”

“With momentum in all of our businesses as we enter the second half of 2025, I look forward to reporting on our continued progress. We remain committed to long-term value creation through portfolio diversification and profitable growth.”

The CEO’s presentation on the Q2 and H1 2025 Results is available at the following link: www.biosyent.com/investors/